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Background:  The  association  of  atrial  fibrillation  (AF)  with  sudden  death  and  the  difference  in prognostic
significance  between  paroxysmal  and  non-paroxysmal  AF remains  unclear  in patients  with  hypertrophic
cardiomyopathy  (HCM).  Our  aim  was to  investigate  the  clinical  significance  of AF,  and to  assess  the
prognostic  difference  between  paroxysmal  and  non-paroxysmal  AF  in  HCM  patients.
Methods:  The  study  included  430  HCM  patients.  Documentation  of  AF was  based on  electrocardiograms
obtained  either  after  the  acute  onset  of  symptoms  or fortuitously  during  routine  examination  of asymp-
tomatic  patients.
Results: AF  was  detected  in  120  patients  (27.9%).  In the  patients  with  AF, syncope  and  non-sustained
ventricular  tachycardia  were  more  frequent  and  the  left  atrial  dimension  was  larger.  Multivariate  analysis
showed  that AF was  an  independent  determinant  of the  outcome,  including  the  risk  of  HCM-related
death (adjusted  hazard  ratio  3.57,  p < 0.001)  and sudden  death (adjusted  hazard  ratio  2.61,  p  =  0.038).
When  patients  with  AF were  divided  into  subgroups  with paroxysmal  AF  (n = 75)  or non-paroxysmal  AF
(n  =  45),  only  paroxysmal  AF was  identified  as an  independent  determinant  of the  outcome,  including  the
risk  of  HCM-related  death  (adjusted  hazard  ratio  5.24,  p <  0.001)  and  sudden  death  (adjusted  hazard  ratio
4.67,  p  = 0.002).
Conclusions:  AF  is  a  common  supraventricular  arrhythmia  in HCM  and  has  an  adverse  influence on
the  prognosis.  In addition,  each  type  of AF  had  a different  clinical  impact,  with  paroxysmal  AF being
a  significant  independent  determinant  of  an  adverse  outcome,  including  sudden  death.
© 2013  Japanese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
Introduction
Hypertrophic cardiomyopathy (HCM) is a unique cardiovascu-
lar disease with a diverse clinical course [1–7]. Atrial fibrillation
(AF) is an important arrhythmia that is associated with systemic
thromboembolism, heart failure, and death in patients with HCM
[8–12]. Previous clinical cohort studies have shown that AF is asso-
ciated with a substantial increase in the overall risk of HCM-related
death, but not sudden death [8,13]. On the other hand, there have
been several reports of AF triggering life-threatening ventricular
arrhythmias [14–20]. It thus remains controversial whether AF is
associated with sudden death in patients with HCM. In addition,
few studies have assessed the difference in clinical impact between
the subsets of AF (paroxysmal or non-paroxysmal).
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Therefore, in the present study, we investigated the clinical sig-
nificance of AF in HCM patients who were diagnosed and followed
at our hospital, as well as the prognostic impact of paroxysmal AF
vs. non-paroxysmal AF.
Methods
Study patients
The study population included 430 patients with a clinical diag-
nosis of HCM who were enrolled consecutively from 1980 to 2003 at
Tokyo Women’s Medical University Hospital (Tokyo, Japan). Initial
evaluation was defined as the first clinical assessment during which
an echocardiographic diagnosis of HCM was made. The most recent
evaluation was  ascertained on review at the clinic or by telephone
interview. Patients who had suffered from non-fatal cardiac arrest
or resuscitated cardiac arrest at the time of referral to our hospital
were excluded. This study was  carried out according to the princi-
ples of the Helsinki Declaration, and the protocol was approved by
the ethics committee of our hospital.
0914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Definitions
The diagnosis of HCM was based on echocardiographic identifi-
cation of severe hypertrophy of the left ventricle in the absence of
another systemic or cardiac disease that was capable of producing
similar hypertrophy [10,11]. Left ventricular outflow tract obstruc-
tion was defined as systolic obstruction (a gradient ≥30 mm Hg on
continuous-wave Doppler echocardiography) of the left ventricular
outflow tract at rest [10,11].
End-stage HCM was defined by the detection of left ventricular
ejection fraction <50% at rest, reflecting global systolic dysfunction,
on two-dimensional echocardiography without a history of surgical
or ablative septal reduction therapy during the follow-up period
[4].
Documentation of AF was based on electrocardiograms obtained
either after the acute onset of symptoms or fortuitously during
routine examination of patients without symptoms [8]. AF was
defined as paroxysmal when it was self-terminating within 7 days,
or when sinus rhythm was successfully restored by electrical or
pharmacologic cardioversion within 48 h [21]. AF was defined as
non-paroxysmal when it progressed to persistent (sustained AF
beyond 7 days or successfully restored by electrical or pharma-
cologic cardioversion after 48 h of AF), longstanding-persistent
(continuous AF of greater than 12 months’ duration), and perma-
nent (AF for which a decision has been made not to restore or
maintain sinus rhythm by any means) in this analysis [21]. Patients
whose AF evolved from paroxysmal to non-paroxysmal during
follow-up were classified into the non-paroxysmal AF group.
In all patients, ambulatory electrocardiograms covering at least
24 h were reviewed for the detection of non-sustained ventricular
tachycardia, which was defined as a minimum of three consecutive
ventricular beats at a rate ≥120/min [10,11].
For survival analysis, the following 3 modes of HCM-related
death were defined [22]: (1) sudden and unexpected death, which
meant collapse in the absence or <1 h after the onset of symptoms
in a patient who had previously been relatively stable (including
resuscitated cardiac arrest); (2) heart failure-related death, which
was defined as occurring after progressive cardiac decompensation
for >1 year before death, particularly if complicated by pulmonary
edema or evolution to end-stage HCM; and (3) stroke-related death,
which was defined as death from ischemic stroke.
The following four clinical features were defined as estab-
lished major primary prevention risk factors for sudden death
on the basis of previous reports [10,11]: (1) a family history of
sudden death; (2) severe left ventricular hypertrophy (left ven-
tricular wall thickness in any myocardial segment ≥30 mm on
two-dimensional echocardiography); (3) non-sustained ventricu-
lar tachycardia (three or more consecutive ventricular beats at a
rate ≥120/min); and (4) unexplained syncope. Abnormal exercise
blood pressure was excluded from the analysis because exercise
tests were not performed in all study HCM patients.
Echocardiography
Echocardiographic studies were performed with commercially
available equipment. Complete two-dimensional, M-mode, and
Doppler studies were done in the left lateral decubitus position
or the supine position, using the standard parasternal, apical, and
subcostal views. The M-mode left atrial end-systolic dimension
was measured in the parasternal long-axis view. The severity and
distribution of left ventricular hypertrophy were assessed in the
short-axis view by dividing the left ventricular wall into four seg-
ments (anterior septum, posterior septum, anterolateral wall, and
posterior wall) at the level of the mitral valve and also at the pap-
illary muscles. Maximal left ventricular wall thickness was  defined
as the greatest thickness in any single segment. Left ventricular
outflow tract obstruction was  quantified by continuous-wave
Doppler echocardiography under resting conditions.
Statistical analysis
Analyses were performed with SAS system ver. 9.1 software (SAS
Institute, Cary, NC, USA). Data are expressed as the mean ± standard
deviation or as frequencies. Student’s t-test was used to com-
pare continuous variables, while the chi-squared test or Fisher’s
exact test (when the expected value was <5) were used to com-
pare discrete variables between patients with or without AF and
patients with paroxysmal AF or non-paroxysmal AF. The proba-
bility of HCM-related death and sudden death was  estimated by
the Kaplan–Meier method, after which the log-rank test was used
to compare survival curves. Cox proportional-hazards regression
analysis was used to calculate hazard ratios and 95% confidence
intervals for the relation between AF and survival. A p-value <0.05
was considered statistically significant in all analyses.
Results
Baseline characteristics of the HCM patients with and without AF
Among the 430 patients enrolled with HCM, AF was documented
in 120 patients and its prevalence was 27.9%. The baseline charac-
teristics of the patients with and without AF are shown in Table 1.
Onset of AF was  detected at ages from 21 to 84 years (average:
56 ± 13 years). There were no significant differences with respect
to gender, family history of sudden death, or maximum left ven-
tricular wall thickness between the patients with and without AF.
The patients with AF were older than those without AF, but the
difference was not significant. In the AF group, syncope was more
frequent, non-sustained ventricular tachycardia was documented
more often, and the left atrial dimension was larger than in the
group without AF. In contrast, left ventricular outflow tract obstruc-
tion was significantly more frequent among patients without AF.
Outcome in patients with or without AF
Among the 120 patients with AF, 22 (18%) died of causes related
to HCM during a mean follow-up period of 12.1 ± 7.3 years, includ-
ing 16 patients (13%) with sudden death, 4 (3.3%) who died of heart
Table 1
Clinical features of HCM  patients with or without AF.
Patients with AF Patients without AF p value
Number of patients, n
(%)
120 (27.9) 310 (72.1)
Age at diagnosis (years) 52.4 ± 13.0 49.7 ± 15.1 0.089
Male, n (%) 86 (71.7) 199 (64.2) 0.175
Duration of follow-up
(years)
12.1 ± 7.3 10.7 ± 7.3 0.083
Family history of
sudden death, n (%)
16 (13.3) 27 (8.7) 0.210
Syncope, n (%) 35 (29.2) 31 (10.0) <0.001
Non-sustained
ventricular
tachycardia, n (%)
70 (58.3) 102 (32.9) <0.001
Echocardiographic findings
Outflow tract
gradient ≥30 mm Hg,
n (%)
17 (14.2) 85 (27.4) 0.006
Maximum wall
thickness (mm)
19.9 ± 4.1 19.4 ± 4.1 0.264
Left atrial dimension
(mm)
41.8  ± 8.7 35.1 ± 6.4 <0.001
Values with ± represent the mean ± SD. AF, atrial fibrillation; HCM,  hypertrophic
cardiomyopathy.
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failure, and 2 (1.7%) who died of HCM-related ischemic stroke. Pro-
gression to end-stage HCM was more likely in the AF group than
in those without AF [n = 25 (20.8%) vs. n = 24 (7.7%), p < 0.001]. In
addition, nonfatal ischemic stroke was significantly more frequent
in the AF group than in patients without AF [n = 32 (26.7%) vs. n = 16
(5.2%), p < 0.001]. According to univariate analysis, the AF group had
a significantly greater risk of HCM-related death than the patients
without AF (p < 0.001, Fig. 1A). The probability of sudden death
among patients from the AF group was also significantly higher
than among patients without AF (p < 0.001, Fig. 1B). When multi-
variate analysis was done with AF, enlarged left atrium ≥46 mm
[23], left ventricular outflow tract obstruction [24], and the four
major risk factors for sudden death (family history of sudden death,
maximum left ventricular wall thickness ≥30 mm,  non-sustained
ventricular tachycardia, and unexplained syncope), it was found
that AF was an independent determinant of the outcome, including
the risk of HCM-related death (adjusted hazard ratio 3.57, 95% con-
fidence interval 1.70–7.49, p < 0.001) and the risk of sudden death
(adjusted hazard ratio 2.61, 95% confidence interval 1.06–6.47,
p = 0.038).
Comparison between paroxysmal AF and non-paroxysmal AF
Among the 120 patients with AF, paroxysmal AF was docu-
mented in 75 patients (63%) and non-paroxysmal AF was  detected
in 45 patients (37%). Twenty-eight (23%) patients showed evo-
lution from paroxysmal AF to non-paroxysmal AF during the
follow-up period. These patients whose AF evolved from parox-
ysmal to non-paroxysmal (n = 28) were similar to the patients
with non-paroxysmal AF from the beginning (n = 17), and no
statistically significant differences were observed between the
two groups in terms of age at diagnosis (54.6 ± 10.3 years vs.
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Fig. 1. Outcome in HCM patients with or without AF. Cumulative probability
(Kaplan–Meier estimate) of overall HCM-related death (A) and sudden death (B)
in  120 patients who  developed AF during the follow-up period compared to 310
patients without AF. AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy.
51.2 ± 9.4 years, p = 0.283), maximum wall thickness
(20.2 ± 4.5 mm vs. 19.4 ± 3.4 mm,  p = 0.531), left atrial dimen-
sion (41.9 ± 9.3 mm vs. 47.1 ± 9.3 mm,  p = 0.078), gender (male
67.9% vs. 94.1%, p = 0.064), prevalence of syncope (25.0% vs.
17.6%, p = 0.719), non-sustained ventricular tachycardia (71.4% vs.
58.8%, p = 0.582), family history of sudden death (14.3% vs. 11.8%,
p > 0.999), and HCM-related death rate (14.3% vs. 11.8%, log-rank
p = 0.797). In addition, all HCM-related events occurred after the
evolution to non-paroxysmal AF in patients with AF evolved from
paroxysmal to non-paroxysmal. Therefore, we classified these
patients into the non-paroxysmal AF group (total n = 45) in the
following analysis. The baseline characteristics of the 75 patients
with paroxysmal AF and 45 patients with non-paroxysmal AF are
shown in Table 2. There was  no significant difference in the age
at diagnosis of HCM, age at onset of AF, and gender between the
patients with paroxysmal or non-paroxysmal AF. In addition, there
was no significant difference in the occurrence of syncope, the
severity of left ventricular hypertrophy, the prevalence of non-
sustained ventricular tachycardia, and the family history of sudden
death. In the patients with paroxysmal AF, left ventricular outflow
tract obstruction was  significantly more frequent than in those
with non-paroxysmal AF. In contrast, the left atrial dimension was
larger in the patients with non-paroxysmal AF than in those with
paroxysmal AF.
Outcome of paroxysmal AF and non-paroxysmal AF
Sixteen out of 75 patients with paroxysmal AF (29%) suffered
from HCM-related death, including sudden death (n = 14, 19%) and
heart failure-related death (n = 2, 2.7%). Among the 45 patients with
non-paroxysmal AF, 6 (13%) died of causes related to HCM, includ-
ing 2 (4.4%) who died suddenly, 2 (4.4%) who died of heart failure,
and 2 (4.4%) who  died of HCM-related ischemic stroke (Fig. 2). There
was a significant difference in the mean interval from the onset of
AF to HCM-related death between patients with paroxysmal AF and
those with non-paroxysmal AF (5.1 ± 4.2 years vs. 11.9 ± 8.3 years,
p = 0.020). According to univariate analysis, paroxysmal AF was
associated with a marked increase in the risk of both HCM-related
death (p < 0.001, Fig. 3A) and sudden death (p < 0.001, Fig. 3B). Non-
paroxysmal AF was a substantial risk factor for HCM-related death
Table 2
Clinical features of HCM patients with paroxysmal AF or non-paroxysmal AF.
Paroxysmal AF Non-paroxysmal AF p value
Number of patients, n
(%)
75 (62.5) 45 (37.5)
Age at diagnosis of
HCM (years)
51.8 ± 14.5 53.3 ± 10.0 0.535
Age  at onset of AF
(years)
56.5 ± 13.3 55.7 ± 12.5 0.744
Male, n (%) 51 (68.0) 35 (77.8) 0.346
Duration of follow-up
(years)
11.0 ± 7.7 13.8 ± 6.2 0.042
Family history of
sudden death, n (%)
10 (13.3) 6 (13.3) >0.999
Syncope, n (%) 25 (33.3) 10 (22.2) 0.276
Non-sustained
ventricular
tachycardia, n (%)
40 (53.3) 30 (66.7) 0.214
Echocardiographic findings
Outflow tract
gradient ≥30 mm Hg,
n (%)
16 (21.3) 1 (2.2) 0.008
Maximum wall
thickness (mm)
19.8 ± 4.1 19.9 ± 4.1 0.899
Left atrial dimension
(mm)
40.5 ± 7.9 43.9 ± 9.6 0.040
Values with ± represent the mean ± SD. AF, atrial fibrillation; HCM, hypertrophic
cardiomyopathy.
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Fig. 2. Mode of death in HCM patients with paroxysmal AF or non-paroxysmal AF.
Sudden death was  the most common cause of death among patients with parox-
ysmal AF who died of HCM-related causes. In contrast, no trend was  found in the
mode of death among patients with non-paroxysmal AF. AF, atrial fibrillation; HCM,
hypertrophic cardiomyopathy.
(p = 0.029, Fig. 3A), but not for sudden death (p = 0.745, Fig. 3B).
When multivariate analysis was done with entry of paroxysmal AF,
non-paroxysmal AF, left atrial enlargement (≥46 mm),  left ventri-
cular outflow tract obstruction, and the four established major risk
factors for sudden death, paroxysmal AF was identified as an inde-
pendent determinant of the outcome, including the risk of HCM-
related death (adjusted hazard ratio 5.24, 95% confidence interval
2.35–11.7, p < 0.001) and the risk of sudden death (adjusted hazard
ratio 4.67, 95% confidence interval 1.80–12.1, p = 0.002). In contrast,
non-paroxysmal AF was not identified as an independent risk factor
for HCM-related death (adjusted hazard ratio 2.36, 95% confidence
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Fig. 3. Outcome in HCM patients with paroxysmal AF or non-paroxysmal AF. The
cumulative probability (Kaplan–Meier estimate) of overall HCM-related death (A)
and sudden death (B) is shown for HCM patients with paroxysmal AF (n = 75) or non-
paroxysmal AF (n = 45) during the follow-up period vs. 310 HCM patients without
AF.  AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy.
interval 0.843–6.63, p = 0.102) or sudden death (adjusted hazard
ratio 0.843, 95% confidence interval 1.72–4.14, p = 0.834).
Discussion
In the present single-center HCM cohort, AF was documented in
28% of the patients. The patients with AF were more likely to have
prognostic risk factors, including syncope, non-sustained ventri-
cular tachycardia, and left atrial enlargement, when compared to
the patients without AF, but multivariate analysis revealed that AF
was still an independent determinant of both HCM-related death
and sudden death. Furthermore, investigation of the difference
between paroxysmal AF and non-paroxysmal AF demonstrated
that only paroxysmal AF was strongly associated with both HCM-
related death and sudden death.
AF is the most common supraventricular arrhythmia in HCM
patients. In our cohort of 430 patients with HCM, the preva-
lence of AF was 28%, which was  similar to that found in previous
cohort studies [3,8,10]. We  also divided the patients with AF,
according to expert consensus statement on AF, into paroxysmal
and non-paroxysmal AF groups [21]. We defined non-paroxysmal
AF as relatively established arrhythmia (persistent, longstanding-
persistent, and permanent AF) or as AF that progressed from
paroxysmal to non-paroxysmal during follow-up. Although we
realize the limitations of this definition, it allowed comparison
between pure paroxysmal AF and other forms. In the present study,
63% of the patients with AF had paroxysmal AF, a higher percent-
age than in previous studies which showed a prevalence of less than
50% among HCM patients with AF [1,8,25]. A possible explanation
for the higher percentage of paroxysmal AF in the present patient
cohort is that our hospital is a tertiary referral center and even
subclinical paroxysmal AF without symptoms may be detected by
careful examinations (including 24-h ambulatory electrocardiogra-
phy) that are done several times a year. Another possible reason is
that patients with AF who are at risk of hemodynamic deterioration
may  be referred to our center for aggressive treatment to prevent
progression to non-paroxysmal AF, including amiodarone therapy
and electrical cardioversion within 48 h. Despite this being a highly
selected population of HCM patients from a single large tertiary
referral center in Japan, our study revealed some interesting epi-
demiologic information about paroxysmal and non-paroxysmal AF
in a relatively large cohort.
The present study identified AF as a substantial risk for overall
HCM-related death and our results also demonstrated an associ-
ation of AF with sudden death. A strong independent association
between AF and HCM-related mortality was previously demon-
strated by Olivotto and colleagues in a community-based HCM
population, and this finding is consistent with our results [8]. How-
ever, no association was detected between AF and sudden death in
a previous study [8], and AF is not listed as a risk factor for sudden
death in the current guideline for HCM [11]. On the other hand,
it has been suggested that in certain susceptible HCM patients,
AF may  trigger life-threatening ventricular arrhythmias [10,26].
Therefore, the relationship between AF and sudden death remains
controversial in patients with HCM, and this is an important area
for further research.
In the present study, we  investigated the difference between
the prognostic influence of paroxysmal AF and non-paroxysmal
AF. Few studies have separately analyzed the prognostic impact of
these two  subsets of AF on the clinical course of HCM, especially
sudden death. Therefore, current guidelines do not distinguish
between paroxysmal and non-paroxysmal AF [11]. In our present
HCM cohort, sudden death was the most common cause of death
among patients with paroxysmal AF who died of HCM-related
causes, and multivariate analysis identified paroxysmal AF as a
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significant independent determinant of sudden death. Further-
more, Olivotto et al. similarly reported that 7 out of 45 patients
(15.6%) who exclusively had paroxysmal AF experienced sudden
unexpected death, while only 6 out of 62 patients (9.7%) with
chronic AF died suddenly [8]. On the other hand, no definite trend in
the mode of death was found for patients with non-paroxysmal AF
in the present study, as shown in Fig. 2. The disparity of the impact
of these two types of AF on sudden death suggests that paroxysmal
AF may  play an important and decisive role in triggering lethal car-
diac events, and emphasizes the necessity for aggressive treatment
during the paroxysmal phase of AF in HCM patients [27,28].
Several mechanisms by which ventricular arrhythmia could be
directly induced by AF with a rapid ventricular response have
been proposed including silent myocardial ischemia [15,19,20],
enhanced atrioventricular node conduction [19], and short-long
short ventricular cycle sequences followed by ventricular tachycar-
dia [14,15]. Patients with HCM are more susceptible to myocardial
ischemia because of small vessel abnormalities, such as thick-
ened walls and limited luminal area [2,29,30], and this has been
regarded as one of the most essential pathophysiological features
that promotes ischemic damage to the ventricular myocardium
[29,31,32] and influences the outcome of HCM [33,34]. In the set-
ting of acute hemodynamic changes, tachycardia, or both, there is
an increase in the oxygen demand of the hypertrophied ventricu-
lar myocardium and elevation of intraventricular pressure, so the
ventricular myocardium of HCM patients is exposed to additional
factors promoting ischemia. It is thus possible that paroxysmal
episodes of AF are responsible for acute clinical deterioration as
a result of reduced diastolic filling and reduced cardiac output,
with such adverse hemodynamic effects being due to an incre-
ment of the ventricular rate (caused by enhanced atrioventricular
conduction) and loss of atrial contraction following the onset of
AF, particularly in patients who have left ventricular hypertrophy
associated with pre-existing diastolic dysfunction [8,19,20]. Con-
sequently, the combination of a sudden rapid ventricular response
and these abrupt hemodynamic changes during paroxysmal AF
could cause myocardial ischemia [20,35], which may  augment
potential arrhythmogenic substrates and lead to life-threatening
ventricular tachyarrhythmia. However, such a hypothesis cannot
apply to all HCM patients with paroxysmal AF who die suddenly,
so further studies are needed to clarify the relationship between
paroxysmal AF and sudden death in HCM.
The ventricular response during AF is influenced by various
factors, such as medications, autonomic tone, and the intrinsic
refractoriness of the atrioventricular node. Provided that atrioven-
tricular conduction is not blocked, the ventricular rate increases
when the atrial rate is relatively slow during AF. Conversely, a
faster atrial rate is associated with a slower ventricular rate because
of concealed conduction in the atrioventricular node that alters
atrioventricular nodal refractoriness to slow or block subsequent
atrial impulses [36]. Shortening of the atrial fibrillatory cycle length,
which is inversely related to atrial fibrillatory rate, and atrial
refractoriness are hallmarks of atrial electrical remodeling [37]. An
electrophysiological study in dogs has demonstrated that the aver-
age atrial fibrillatory rate is significantly shorter in patients with
chronic AF than in those with paroxysmal AF [38]. Moreover, func-
tional electrophysiological remodeling of the atrioventricular node
occurs during long-term AF, which could lead to spontaneous slow-
ing of the ventricular rate [39]. These observations suggest that
a sudden rapid ventricular response will not easily occur in non-
paroxysmal AF, especially in patients receiving pharmacological
rate control therapy. Therefore, refractoriness to a sudden rapid
ventricular response is one possible reason why non-paroxysmal
AF showed no significant association with an increased incidence
of sudden death in our HCM cohort. Interestingly, the mean inter-
val from the occurrence of AF to HCM-related death in our patients
with non-paroxysmal AF was significantly longer than in those with
paroxysmal AF, representing the difference of prognostic impact
between these two types of AF.
Limitations
The present investigation was retrospective and was  done at a
single tertiary center, so it may  have had certain inherent selec-
tion biases. Further large-scale, multicenter, and/or multinational
studies are needed to extend the current findings. In addition, the
diagnosis of AF in this study was mainly based on electrocardio-
grams and 24-h ambulatory electrocardiograms, which are not fully
reliable for detecting paroxysmal AF, so it is therefore likely that
we underestimated the true prevalence of AF among patients with
HCM. Furthermore, we  should examine the prognostic effect of
drug use in study HCM patients, especially of antiarrhythmic drugs
because of their proarrhythmic effect. In this study, however, we
could not evaluate it in detail, because we cannot fully access the
data of drug treatment in all study HCM patients.
Conclusions
In our HCM patient cohort, AF was  a common supraventricular
arrhythmia and it had an adverse effect on the prognosis, includ-
ing sudden death. We  also demonstrated that each type of AF had
a different clinical impact, with paroxysmal AF being a significant
independent determinant of an adverse outcome. It may  be neces-
sary to give careful consideration to the prevention of sudden death
in HCM patients during the paroxysmal phase of AF.
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